 MINNEAPOLIS, April 6, 2021 PRNewswire -- Bio-Techne Corporation NASDAQ: TECH today announced it has completed the acquisition of Asuragen, Inc. The transaction included initial consideration of 215 million in cash plus contingent consideration of up to 105 million upon the achievement of certain future milestones. The Asuragen acquisition adds a leading portfolio of best-in-class molecular diagnostic and research products, including genetic screening and oncology testing kits, molecular controls, a Good Manufacturing Practice GMP-compliant 50,000 square foot manufacturing facility and a CLIA-certified laboratory, plus a team with deep expertise navigating products through the global diagnostic regulatory environment. 